Human Immune System Based Testing

Neglected Diseases, Orphan Diseases, and

Diseases of Global Health Significance

Praedicare houses several of the infectious diseases physicians, public health experts, and mathematical modelers who pioneered the techniques, methods, and skills to allow the approaches described here to effect antimicrobial resistance emergence mitigation.

The specialists at Praedicare came out of a global health and neglected health background in academia where they were full professors, and as drug developers in biotech companies that developed anti-infectives for tuberculosis, parasitic diseases, non-tuberculous mycobacteria, leprosy, HIV, hepatitis C, and the global problem of developing dosing regimens in an increasingly obese world. We have partnered with international public/private organizations, biotech companies, pharmaceutical companies, governmental funding bodies, and several universities to develop treatments.

  • Obesity

  • Leishmania hollow fiber and patient work

  • Cerebral malaria with human blood brain barrier hollow fiber models

  • Other bacterial neglected diseases

  • Other regional viral neglected diseases [RNA-viruses]

  • Hepatitis C work

  • Development of long-acting/slow release anti-retrovirals

  • Non-tuberculous mycobacteria

  • TuberculosisContact Section Desktop

INTERESTED IN LEARNING MORE?

Contact Us Today

21

56

Number of Biopharma

Companies Worked With

Number of Projects

Worked On

Neglected Diseases, Orphan Diseases, and

Diseases of Global Health Significance

Praedicare houses several of the infectious diseases physicians, public health experts, and mathematical modelers who pioneered the techniques, methods, and skills to allow the approaches described here to effect antimicrobial resistance emergence mitigation.

The specialists at Praedicare came out of a global health and neglected health background in academia where they were full professors, and as drug developers in biotech companies that developed anti-infectives for tuberculosis, parasitic diseases, non-tuberculous mycobacteria, leprosy, HIV, hepatitis C, and the global problem of developing dosing regimens in an increasingly obese world. We have partnered with international public/private organizations, biotech companies, pharmaceutical companies, governmental funding bodies, and several universities to develop treatments.

  • Obesity

  • Leishmania hollow fiber and patient work

  • Cerebral malaria with human blood brain barrier hollow fiber models

  • Other bacterial neglected diseases

  • Other regional viral neglected diseases [RNA-viruses]

  • Hepatitis C work

  • Development of long-acting/slow release anti-retrovirals

  • Non-tuberculous mycobacteria

  • Tuberculosis

INTERESTED IN LEARNING MORE?

Contact Us Today

19

Number of Biopharma

Companies Worked With

51

Number of Projects

Worked On